PAVmed Inc. is a diversified medical technology company focused on innovating solutions that enhance patient care and improve health outcomes. One of its key subsidiaries, Lucid Diagnostics, has developed the EsoGuard® DNA test, which is the first and only diagnostic test designed to detect esophageal precancer and cancer. This groundbreaking test utilizes next-generation sequencing to analyze genetic material from cells collected from the esophagus through a quick, non-invasive procedure. With a sensitivity of approximately 90% and a negative predictive value of around 99%, EsoGuard allows for early detection of conditions such as Barrett's esophagus and esophageal adenocarcinoma without the need for sedation or endoscopy, making it a significant advancement in the field of medical diagnostics.

In addition to EsoGuard, PAVmed's subsidiary Veris Health is dedicated to enhancing personalized cancer care through remote patient monitoring and a digital health platform. This platform integrates connected health devices to provide comprehensive support for patients undergoing cancer treatment. The company's innovative approach is further exemplified by its EsoCheck with Collect+Protect™ technology, a cell collection device that enables targeted sampling of esophageal cells without endoscopy, facilitating a seamless diagnostic process. Through these technologies, PAVmed aims to transform healthcare delivery and improve outcomes for patients at risk of esophageal cancer.

United States

PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.

PAVmed Inc.

Company Details